TScan Therapeutics Stock (NASDAQ:TCRX)

Forecast Revenue Ownership Financials Chart

Previous Close

$1.93

52W Range

$1.02 - $7.31

50D Avg

$1.60

200D Avg

$2.58

Market Cap

$105.82M

Avg Vol (3M)

$583.49K

Beta

0.97

Div Yield

TCRX Company Profile

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

200

IPO Date

Jul 16, 2021

Website

TCRX Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 24
Reportable Segment	$2.82M

Fiscal year ends in Dec 24 | Currency in USD

TCRX Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$2.82M	$21.05M	$13.54M
Operating Income	$-134.82M	$-93.46M	$-66.64M
Net Income	$-127.50M	$-89.22M	$-65.81M
EBITDA	$-119.74M	$-80.10M	$-59.91M
Basic EPS	$-1.14	$-1.36	$-2.74
Diluted EPS	$-1.14	$-1.36	$-2.74

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
INAB	IN8bio, Inc.
ANNX	Annexon, Inc.
HOWL	Werewolf Therapeutics, Inc.
ERAS	Erasca, Inc.
DRMA	Dermata Therapeutics, Inc.
WVE	Wave Life Sciences Ltd.
ELEV	Elevation Oncology, Inc.
ZURA	Zura Bio Limited